Literature DB >> 7207767

Phenytoin: pharmacokinetics and clinical therapeutics.

C W Olanow, A L Finn.   

Abstract

Phenytoin is a highly effective anticonvulsant medication that is considered to be the treatment of choice for generalized major motor and focal epileptic seizures. An understanding of the pharmacokinetic properties of phenytoin greatly facilitates the management of seizure patients. The judicious use of serum-monitoring techniques coupled with careful clinical evaluations enable one to obtain the optimal anticonvulsant effect, freedom from dose-related toxicity, and the avoidance of unnecessary polypharmacy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7207767     DOI: 10.1227/00006123-198101000-00022

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Peri-operative prophylaxis with phenytoin: dosage and therapeutic plasma levels.

Authors:  A Levati; G Savoia; F Zoppi; L Boselli; C Tommasino
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 2.  Seizure prophylaxis for brain tumour patients. Brief review and guide for family physicians.

Authors:  C B Agbi; M Bernstein
Journal:  Can Fam Physician       Date:  1993-05       Impact factor: 3.275

3.  Phenytoin plasma levels after intraoperative administration, for the prevention of post-craniotomy seizures.

Authors:  M Tsolaki; M Yannacou-Peftoulidou; P Grammaticos; E Sofianos; G Foroglou
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

4.  Interagency regulatory liaison group workshop on reproductive toxicity risk assessment.

Authors:  C A Kimmel; G L Kimmel; V Frankos
Journal:  Environ Health Perspect       Date:  1986-04       Impact factor: 9.031

5.  Efficacy of levetiracetam compared with phenytoin in prevention of seizures in brain injured patients: A meta-analysis.

Authors:  Lin Zhao; Yu-Peng Wu; Jin-Long Qi; Yong-Qiang Liu; Kai Zhang; Wen-Ling Li
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.